Michael Nicholas Greco

USPTO Granted Patents = 45 (Patent Applications = 9)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 65(Granted Patents)

Location History:

Spring House, PA (US) (2013)
Lansdale, PA (US) (1991 - 2022)

Company Filing History:

19 out of 2,076

Janssen Pharmaceutica Nv

patents

14 out of 363

Ortho-mcneil Pharmaceutical Corp.

Ortho Pharmaceutical Corporation

patents

5. 1 out of 1

Beta Pharma (shanghai) Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 1991-2025

Loading Chart...

45 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),

2. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),

3. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),

4. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),

5. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),

6. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),

7. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),

8. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),

9. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),

10. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),

11. 10118900 - Benzimidazole derivatives useful as CB-1 inverse agonists (2018-11-06),

12. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),

13. 9815790 - Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists (2017-11-14),

14. 9732061 - Cinnoline derivatives useful as CB-1 receptor inverse agonists (2017-08-15),

15. 9682955 - Quinazoline derivatives useful as CB-1 inverse agonists (2017-06-20),

Title: Michael Nicholas Greco: Innovator in Pharmaceutical Formulations

Introduction: Michael Nicholas Greco, based in Lansdale, PA, has made significant contributions to the field of pharmaceuticals, with a remarkable portfolio consisting of 43 patents. His innovations primarily focus on the development of targeted therapies aimed at treating various medical conditions, including cancers related to epidermal growth factor receptor (EGFR) mutations.

Latest Patents: Greco's latest patents include groundbreaking formulations that target specific diseases through innovative molecular designs. One notable patent details "Pharmaceutical formulations of (2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and its salts." This formulation aims to treat or prevent diseases mediated by mutated forms of the EGFR, particularly various cancers. Another significant patent describes "Substituted 2-anilinopyrimidine derivatives as EGFR modulators." This application presents novel derivatives useful for treating cancer through EGFR modulation, highlighting Greco's commitment to advancing cancer therapies.

Career Highlights: Throughout his career, Michael Nicholas Greco has collaborated with prominent companies in the pharmaceutical sector, including Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation. His expertise in creating effective pharmaceutical formulations has established him as a key figure in drug development processes aimed at improving patient outcomes.

Collaborations: Greco’s collaborative efforts have included working alongside talented professionals such as Michael Hawkins and Eugene Powell. These partnerships have been instrumental in enhancing the research and development of innovative pharmaceutical solutions.

Conclusion: Michael Nicholas Greco continues to be a leading innovator in the pharmaceutical industry, with a focus on developing targeted therapies for cancer treatment through his extensive patent portfolio. His dedication to advancing medical science through innovative formulations showcases his impact on the field and marks him as a significant contributor to the ongoing fight against cancer.

This text is generated by artificial intelligence and may not be accurate.